Novavax, Inc. (NVAX)
10.34
+0.02
(+0.15%)
USD |
NASDAQ |
Sep 03, 16:00
10.33
0.00 (0.00%)
After-Hours: 20:00
Novavax Research and Development Expense (Annual) : 336.82M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 336.82M |
| December 31, 2024 | 388.77M |
| December 31, 2023 | 656.00M |
| December 31, 2022 | 1.235B |
| December 31, 2021 | 2.535B |
| December 31, 2020 | 747.03M |
| December 31, 2019 | 113.84M |
| December 31, 2018 | 173.80M |
| December 31, 2017 | 168.44M |
| December 31, 2016 | 237.94M |
| December 31, 2015 | 162.64M |
| December 31, 2014 | 79.44M |
| December 31, 2013 | 50.31M |
| Date | Value |
|---|---|
| December 31, 2012 | 26.06M |
| December 31, 2011 | 17.88M |
| December 31, 2010 | 28.03M |
| December 31, 2009 | 25.78M |
| December 31, 2008 | 24.33M |
| December 31, 2007 | 17.60M |
| December 31, 2006 | 11.53M |
| December 31, 2005 | 5.075M |
| December 31, 2004 | 7.369M |
| December 31, 2003 | 10.06M |
| December 31, 2002 | 11.50M |
| December 31, 2001 | 10.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Merck & Co., Inc. | 12.51B |
| Pfizer Inc. | 10.25B |
| Recursion Pharmaceuticals, Inc. | 425.27M |
| Agenus, Inc. | 79.34M |